BD's 2025 Annual Meeting: A Virtual Gathering for Shareholders

Alright, shareholders and investors, mark your calendars! BD (Becton, Dickinson and Company) is hosting its virtual 2025 Annual Meeting of Shareholders on Tuesday, January 28, 2025, at 1:00 p.m. (ET). If you're a shareholder of record as of December 9, 2024, or have a duly authorized proxy, you can attend, vote, and ask questions by visiting . Guests can also join in listen-only mode without a control number. A replay of the webcast will be available on the BD website at for approximately one year following the meeting.

BD, a leading global medical technology company, is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. With over 70,000 employees and a presence in virtually every country, BD is committed to enhancing the safety and efficiency of clinicians' care delivery process, enabling laboratory scientists to accurately detect disease, and advancing researchers' capabilities to develop the next generation of diagnostics and therapeutics.

As a shareholder, you might be wondering how BD's stock performance has compared to its peers and the broader market in the past year. Well, BD's stock has remained relatively stable, with a slight increase of approximately 5% compared to its peers and the broader market. This is a testament to the company's strong financial performance and commitment to growth.

BD's acquisition strategy has also contributed significantly to its growth and market position. In 2019, BD acquired C.R. Bard, a leading medical device company, for $24 billion. This acquisition expanded BD's product portfolio, particularly in the areas of vascular, interventional, and surgical devices. Post-acquisition, BD's revenue grew by 11% in 2020, demonstrating the strategic value of the deal.

To further enhance its competitive advantage, BD could consider targeting companies with innovative technologies in high-growth areas such as digital health, connected devices, and advanced diagnostics. For example, acquiring Medtronic's remote patient monitoring division could strengthen BD's position in the connected health market, while acquiring Illumina's sequencing technology could bolster its diagnostics capabilities.

However, BD faces several risks and challenges that investors should be aware of. These include business risks and uncertainties, global health issues, and regulatory compliance. To mitigate these risks, investors can diversify their portfolios, monitor regulatory developments, evaluate BD's financial health, and consider long-term investments.

In conclusion, BD's 2025 Annual Meeting of Shareholders is an excellent opportunity for shareholders to engage with the company, ask questions, and vote on important matters. With a strong financial performance, strategic acquisitions, and a commitment to growth, BD is well-positioned to continue delivering value to shareholders in the coming years. So, mark your calendars and join the virtual gathering on January 28, 2025!